Table 3.

Numbers of total polyps and adenomas 1 year after initiation of treatment

PlaceboSulindacEtodolac
Subjects with polypectomyn = 48n = 48n = 47
No. of total polyps
 Mean ± SD0.92 ± 1.050.42 ± 0.680.73 ± 0.94
 Median (range)1 (0–4)0 (0–2)0 (0–3)
P valueP = 0.014a P = 0.64
No. of adenomas
 Mean ± SD0.81 ±1.00.42 ± 0.710.68 ± 0.86
 Median (range)1 (0–4)0 (0–2)0 (0–3)
P valueP = 0.034P = 0.61
Polyp-free subjectsn = 9n = 9n = 10
 No. of total polyps
 Mean ± SD0.22 ± 0.440.22 ± 0.440.20 ± 0.42
 Median (range)0 (0–1)0 (0–1)0 (0–1)
P valueP = 1.00P = 0.94
No. of adenomas
 Mean ± SD0.11 ±0.330.22 ± 0.440.20 ± 0.67
 Median (range)0 (0–1)0 (0–1)0 (0–2)
P valueP = 0.54P = 0.93
All subjectsn = 57n = 57n = 57
No. of total polyps
 Mean ± SD0.81 ± 1.010.40 ± 0.700.68 ± 0.89
 Median (range)0 (0–4)0 (0–2)0 (0–3)
P valueP = 0.020P = 0.61
No. of adenomas
 Mean ± SD0.70 ± 0.960.39 ± 0.680.60 ± 0.84
 Median (range)0 (0–4)0 (0–2)0 (0–3)
P valueP = 0.064P = 0.63
  • aSignificant P value by Mann–Whitney U test.